Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021)
Candel Therapeutics' (CADL) quarterly Preferred Stock Liabilities came in at $22.5 million in Q2 2021, little changed year-on-year from $22.5 million in Q2 2020, and down 15.29% quarter-over-quarter from $26.6 million in Q1 2021.
Candel Therapeutics (CADL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Candel Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $22.5 million for Q2 2021.
- Preferred Stock Liabilities for Q2 2021 came in at $22.5 million, changed 0.0% year-over-year; the trailing twelve-month figure through Jun 2021 was $22.5 million (changed 0.0% YoY), and the FY2020 annual result was $22.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $22.5 million for Q2 2021 at Candel Therapeutics, down from $26.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $26.6 million in Q3 2020 to a low of $22.5 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 22.50 Mn |
| Mar 31, 2021 | 26.56 Mn |
| Dec 31, 2020 | 22.50 Mn |
| Sep 30, 2020 | 26.56 Mn |
| Jun 30, 2020 | 22.50 Mn |